Our ambition is to change lives by changing the course of blood cancer.

We’re committed to bringing the potential power of telomerase inhibition to patients with imetelstat.

See imetelstat in action

Latest Updates

Research & Development

Geron announces FDA acceptance of New Drug Application for imetelstat for the treatment of transfusion dependent anemia in patients with lower risk myelodysplastic syndromes (LR MDS)

Learn more

Corporate News

Geron announces the appointment of Gaurav Aggarwal, M.D., to its Board of Directors

Medical Congress

Geron announces IMerge Phase 3 data presentations to be presented at the at the 65th American Society of Hematology (ASH) Annual Meeting

Events

View all

Investor Event

Geron to present at three investor conferences in November

John Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at three investor conferences this month.

For more information:

View now

Investor Event

Watch the replay of our third quarter financial results webcast

Geron management shared third quarter financial results and business highlights.

For more information:

View the video

Research & Development

What if you could kill cancer cells by targeting the enzyme that drives their uncontrolled growth?

Geron is tirelessly pursuing blood cancer treatments with the potential to extend and enhance lives through the unique mechanism of action of telomerase inhibition. Our first-in-class telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease.

Learn about imetelstat